AI Article Synopsis
- Lung transplantation is a critical treatment for end-stage lung disease, but hyperbilirubinemia, although rare, can occur post-surgery, prompting this study to investigate its causes.
- Out of 116 lung transplant patients reviewed, 33 (28.4%) developed hyperbilirubinemia, primarily due to common factors like drug toxicity and sepsis, but 9 (7.8%) had rare causes such as hemophagocytic lymphohistiocytosis (HLH).
- All patients with rare causes of hyperbilirubinemia died despite treatment, highlighting the need for prompt evaluation and management to enhance survival chances after lung transplantation.
Article Abstract
Background: Lung transplantation is the last treatment option for end-stage lung disease, and the number of lung transplantations has been steadily increasing. Hyperbilirubinemia is a rare complication after lung transplantation. The aim of this study was to review rare causes of hyperbilirubinemia after lung transplantation at our center.
Methods: In this single-center study, we retrospectively reviewed the records of 116 consecutive lung transplantation patients who underwent lung transplantation at Severance Hospital and Gangnam Severance Hospital of Yonsei University College of Medicine in South Korea between December 22, 2010 and January 1, 2016. Hyperbilirubinemia was defined as a total bilirubin level exceeding 5 mg/dL for at least 3 days after lung transplantation.
Results: Hyperbilirubinemia occurred in 33 patients (28.4%) who received lung transplants at our institution. Twenty-four cases involved common causes such as drug toxicity, biliary tract stone, sepsis, and bleeding. However, rare causes of hyperbilirubinemia including hemophagocytic lymphohistiocytosis (HLH), thrombotic microangiopathy (TMA), and ischemic cholangiopathy were observed in 9 (7.8%) patients during the study period. All patients with hyperbilirubinemia due to a rare cause died despite aggressive treatment.
Conclusion: Causes of hyperbilirubinemia after lung transplantation are varied, and the prognosis of patients with hyperbilirubinemia arising from rare causes was poor. Therefore, early evaluation and management of hyperbilirubinemia after lung transplantation is important to improve patient outcomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757002 | PMC |
| http://dx.doi.org/10.21037/jtd.2017.11.118 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Short and Long-Term Outcomes of Lung Transplantation from Brain Death vs. Circulatory Death Donors: A Meta-analysis of Comparative Studies.
J Heart Lung Transplant
January 2025
Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN; Division of Thoracic Surgery, Department of Surgery, Mayo Clinic, Rochester, MN. Electronic address:
Objectives: To investigate through a meta-analysis of comparative studies the impact of donor type (brain death DBD vs circulatory death DCD) on the short- and long-term outcomes of lung transplantation(LTx).
Methods: Literature search (terms "lung transplantation" AND "donation after circulatory death") was performed up to July 2022 and studies comparing outcomes of LTx from DCD versus DBD were selected. Primary endpoints were early and long-term mortality.
Scoliosis Progression after Lung Transplantation: Scoliosis after lung transplantation.
Spine J
January 2025
Department of Thoracic Surgery, Kyoto University, Graduate School of Medicine.
Background Context: Scoliosis is a potential postoperative complication of various pediatric cardiothoracic conditions.
Purpose: To investigate the incidence of scoliosis in pediatric lung transplant patients and explore the factors associated with its development.
Study Design: Retrospective observational study PATIENT SAMPLE: 330 consecutive lung transplant recipients at a single institution between April 2002 and June 2022.
In the Twilight of Evidence: Is Bypass Surgery Still on the Table for Cardiac Allograft Vasculopathy?
J Clin Med
December 2024
Department of Cardiology, University Hospital Zurich, 8091 Zurich, Switzerland.
Cardiac allograft vasculopathy (CAV) is a major prognosis-limiting factor in patients undergoing orthotopic heart transplantation (HT). Due to the diffuse involvement of the coronary tree, CAV lesions are often not amenable to percutaneous coronary intervention (PCI), leaving coronary artery bypass grafting (CABG) and retransplantation as primary revascularization options. : The latest guidelines from the International Society for Heart and Lung Transplantation (ISHLT) recognize CABG as a viable option but with a downgraded strength of recommendation.
View Article and Find Full Text PDFRecent Advances and Future Directions in Extracorporeal Carbon Dioxide Removal.
J Clin Med
December 2024
Department of Adult Critical Care, Guy's and St Thomas' NHS Foundation Trust, King's Health Partners, London SE1 9RT, UK.
Extracorporeal carbon dioxide removal (ECCOR) is an emerging technique designed to reduce carbon dioxide (CO) levels in venous blood while enabling lung-protective ventilation or alleviating the work of breathing. Unlike high-flow extracorporeal membrane oxygenation (ECMO), ECCOR operates at lower blood flows (0.4-1.
View Article and Find Full Text PDFEngineered Cellular Therapies for the Treatment of Thoracic Cancers.
Cancers (Basel)
December 2024
Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN 55455, USA.
Thoracic malignancies (lung cancers and malignant pleural mesothelioma) are prevalent worldwide and are associated with high morbidity and mortality. Effective treatments are needed for patients with advanced disease. Cell therapies are a promising approach to the treatment of advanced cancers that make use of immune effector cells that have the ability to mediate antitumor immune responses.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!